{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:50Z","timestamp":1790164010174,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Prospective epidemiologic studies have consistently shown that levels of circulating androgens in postmenopausal women are positively associated with breast cancer risk. However, data in premenopausal women are limited.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>A case-control study nested within the New York University Women's Health Study was conducted. A total of 356 cases (276 invasive and 80 <jats:italic>in situ<\/jats:italic>) and 683 individually-matched controls were included. Matching variables included age and date, phase, and day of menstrual cycle at blood donation. Testosterone, androstenedione, dehydroandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured using direct immunoassays. Free testosterone was calculated.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Premenopausal serum testosterone and free testosterone concentrations were positively associated with breast cancer risk. In models adjusted for known risk factors of breast cancer, the odds ratios for increasing quintiles of testosterone were 1.0 (reference), 1.5 (95% confidence interval (CI), 0.9 to 2.3), 1.2 (95% CI, 0.7 to 1.9), 1.4 (95% CI, 0.9 to 2.3) and 1.8 (95% CI, 1.1 to 2.9; <jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub> = 0.04), and for free testosterone were 1.0 (reference), 1.2 (95% CI, 0.7 to 1.8), 1.5 (95% CI, 0.9 to 2.3), 1.5 (95% CI, 0.9 to 2.3), and 1.8 (95% CI, 1.1 to 2.8, <jats:italic>P<\/jats:italic><jats:sub>trend<\/jats:sub> = 0.01). A marginally significant positive association was observed with androstenedione (<jats:italic>P<\/jats:italic> = 0.07), but no association with DHEAS or SHBG. Results were consistent in analyses stratified by tumor type (invasive, <jats:italic>in situ<\/jats:italic>), estrogen receptor status, age at blood donation, and menopausal status at diagnosis. Intra-class correlation coefficients for samples collected from 0.8 to 5.3 years apart (median 2 years) in 138 cases and 268 controls were greater than 0.7 for all biomarkers except for androstenedione (0.57 in controls).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Premenopausal concentrations of testosterone and free testosterone are associated with breast cancer risk. Testosterone and free testosterone measurements are also highly reliable (that is, a single measurement is reflective of a woman's average level over time). Results from other prospective studies are consistent with our results. The impact of including testosterone or free testosterone in breast cancer risk prediction models for women between the ages of 40 and 50 years should be assessed. Improving risk prediction models for this age group could help decision making regarding both screening and chemoprevention of breast cancer.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr3117","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T15:14:51Z","timestamp":1329405291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Premenopausal serum androgens and breast cancer risk: a nested case-control study"],"prefix":"10.1186","volume":"14","author":[{"given":"Anne","family":"Zeleniuch-Jacquotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Afanasyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Kaaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Scarmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Toniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy E","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,16]]},"reference":[{"key":"2919_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","volume":"94","author":"The Endogenous Hormones Breast Cancer Collaborative Group","year":"2002","unstructured":"The Endogenous Hormones Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002, 94: 606-616. 10.1093\/jnci\/94.8.606.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1677\/erc.1.01038","volume":"12","author":"R Kaaks","year":"2005","unstructured":"Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PHM, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang Claude J, Clavel Chapelon F, Fournier A, Thibaut A, Gonzlez CA, Quirs JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, et al: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005, 12: 1071-1082. 10.1677\/erc.1.01038.","journal-title":"Endocr Relat Cancer"},{"key":"2919_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/ERC-09-0211","volume":"17","author":"C Woolcott","year":"2010","unstructured":"Woolcott C, Shvetsov Y, Stanczyk F, Wilkens L, White K, Caberto C, Henderson B, Le-Marchand L, Kolonel L, Goodman M: Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocr Relat Cancer. 2010, 17: 125-134. 10.1677\/ERC-09-0211.","journal-title":"Endocr Relat Cancer"},{"key":"2919_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/jnci\/djh336","volume":"96","author":"S Missmer","year":"2004","unstructured":"Missmer S, Eliassen AH, Barbieri R, Hankinson S: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004, 96: 1856-1865. 10.1093\/jnci\/djh336.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.bjc.6601517","volume":"90","author":"A Zeleniuch-Jacquotte","year":"2004","unstructured":"Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P: Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer risk: long-term results of a prospective study. Br J Cancer. 2004, 90: 153-159. 10.1038\/sj.bjc.6601517.","journal-title":"Br J Cancer"},{"key":"2919_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1055-9965.EPI-09-0532","volume":"19","author":"L Baglietto","year":"2010","unstructured":"Baglietto L, Severi G, English D, Krishnan K, Hopper J, McLean C, Morris H, Tilley W, Giles G: Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2010, 19: 492-502. 10.1158\/1055-9965.EPI-09-0532.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1023\/A:1025671317220","volume":"14","author":"J Manjer","year":"2003","unstructured":"Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, Lenner P: Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003, 14: 599-607. 10.1023\/A:1025671317220.","journal-title":"Cancer Causes Control"},{"key":"2919_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1055-9965.EPI-04-0375","volume":"14","author":"S Cummings","year":"2005","unstructured":"Cummings S, Lee J, Lui L-Y, Stone K, Ljung B, Cauleys J: Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1047-1051. 10.1158\/1055-9965.EPI-04-0375.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/oxfordjournals.aje.a114596","volume":"125","author":"DK Wysowski","year":"1987","unstructured":"Wysowski DK, Comstock GW, Helsing KJ, Lau HL: Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol. 1987, 125: 791-799.","journal-title":"Am J Epidemiol"},{"key":"2919_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/bjc.1997.183","volume":"75","author":"H Thomas","year":"1997","unstructured":"Thomas H, Key T, Allen D, Moore J, Dowsett M, Fentiman I, Wang D: A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer. 1997, 75: 1075-1079. 10.1038\/bjc.1997.183.","journal-title":"Br J Cancer"},{"key":"2919_CR11","first-page":"575","volume":"9","author":"M Kabuto","year":"2000","unstructured":"Kabuto M, Akiba S, Stevens R, Neriishi K, Land C: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev. 2000, 9: 575-579.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ijc.20403","volume":"112","author":"A Micheli","year":"2004","unstructured":"Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F: Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004, 112: 312-318. 10.1002\/ijc.20403.","journal-title":"Int J Cancer"},{"key":"2919_CR13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1055-9965.1032.13.6","volume":"13","author":"J Page","year":"2004","unstructured":"Page J, Colditz G, Rifai N, Barbieri R, Willett W, Hankinson S: Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1032-1036.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jnci\/dji132","volume":"97","author":"R Kaaks","year":"2005","unstructured":"Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita H, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils C, Gonzalez C, Gurrea A, Critselis E, Khaw K, Krogh V, Lahmann P, Nagel G, Olsen A, Onland-Moret N, Overvad K, Palli D, Panico S, Peeters P, Quir\u00f3s J, Roddam A, et al: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005, 97: 755-765. 10.1093\/jnci\/dji132.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1055-9965.EPI-05-0976","volume":"15","author":"S Tworoger","year":"2006","unstructured":"Tworoger S, Missmer S, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri R, Hankinson S: The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006, 15: 967-971. 10.1158\/1055-9965.EPI-05-0976.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/jnci\/djj376","volume":"98","author":"A Eliassen","year":"2006","unstructured":"Eliassen A, Missmer S, Tworoger S, Spiegelman D, Barbieri R, Dowsett M, Hankinson S: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006, 98: 1406-1415. 10.1093\/jnci\/djj376.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR17","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1186\/bcr2779","volume":"12","author":"J Dorgan","year":"2010","unstructured":"Dorgan J, Stanczyk F, Kahle L, Brinton L: Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res. 2010, 12: R98-10.1186\/bcr2779.","journal-title":"Breast Cancer Res"},{"key":"2919_CR18","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989, 81: 1879-1886. 10.1093\/jnci\/81.24.1879.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7326\/0003-4819-151-10-200911170-00008","volume":"151","author":"U.S. Preventive Services Task Force","year":"2009","unstructured":"U.S. Preventive Services Task Force: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009, 151: 716-726. W-236","journal-title":"Ann Intern Med"},{"key":"2919_CR20","unstructured":"American Cancer Society Guidelines for the Early Detection of Cancer. [http:\/\/www.cancer.org\/Healthy\/FindCancerEarly\/CancerScreeningGuidelines\/american-cancer-society-guidelines-for-the-early-detection-of-cancer]"},{"key":"2919_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.7326\/0003-4819-137-1-200207020-00016","volume":"137","author":"U.S. Preventive Services Task Force","year":"2002","unstructured":"U.S. Preventive Services Task Force: Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002, 137: 56-58.","journal-title":"Ann Intern Med"},{"key":"2919_CR22","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.2002.06.029","volume":"20","author":"R Chlebowski","year":"2002","unstructured":"Chlebowski R, Col N, Winer E, Collyar D, Cummings S, Vogel V, Burstein H, Eisen A, Lipkus I, Pfister D: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002, 20: 3328-3343. 10.1200\/JCO.2002.06.029.","journal-title":"J Clin Oncol"},{"key":"2919_CR23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/archinte.166.20.2260","volume":"166","author":"K Armstrong","year":"2006","unstructured":"Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C, Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C: Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006, 166: 2260-2265. 10.1001\/archinte.166.20.2260.","journal-title":"Arch Intern Med"},{"key":"2919_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1055-9965.EPI-09-0930","volume":"19","author":"EA Waters","year":"2010","unstructured":"Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN, Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN: Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010, 19: 443-446. 10.1158\/1055-9965.EPI-09-0930.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR25","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1096\/fj.99-0863com","volume":"14","author":"J Zhou","year":"2000","unstructured":"Zhou J, Ng S, Adesanya Famuiya O, Anderson K, Bondy CA: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000, 14: 1725-1730. 10.1096\/fj.99-0863com.","journal-title":"FASEB J"},{"key":"2919_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/01.GME.0000055522.67459.89","volume":"10","author":"C Dimitrakakis","year":"2003","unstructured":"Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003, 10: 292-298. 10.1097\/01.GME.0000055522.67459.89.","journal-title":"Menopause"},{"key":"2919_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/gme.0b013e318191747a","volume":"16","author":"C Wood","year":"2009","unstructured":"Wood C, Lees C, Cline JM: Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesterone. Menopause. 2009, 16: 466-476. 10.1097\/gme.0b013e318191747a.","journal-title":"Menopause"},{"key":"2919_CR28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa0707302","volume":"359","author":"S Davis","year":"2008","unstructured":"Davis S, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein G, Hirschberg A, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J: Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008, 359: 2005-2017. 10.1056\/NEJMoa0707302.","journal-title":"N Engl J Med"},{"key":"2919_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.maturitas.2010.12.001","volume":"68","author":"R Glaser","year":"2011","unstructured":"Glaser R, York A, Dimitrakakis C: Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas. 2011, 68: 355-361. 10.1016\/j.maturitas.2010.12.001.","journal-title":"Maturitas"},{"key":"2919_CR30","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1007\/BF02633522","volume":"18","author":"PG Toniolo","year":"1991","unstructured":"Toniolo PG, Pasternack BS, Shore RE, Sonnenschein EG, Koenig KL, Rosenberg C, Strax P, Strax S: Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat. 1991, 18: S23-S26. 10.1007\/BF02633522.","journal-title":"Breast Cancer Res Treat"},{"key":"2919_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/oxfordjournals.aje.a009823","volume":"149","author":"I Kato","year":"1999","unstructured":"Kato I, Toniolo P, Koenig K, Kahn A, Schymura M, Zeleniuch-Jacquotte A: Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol. 1999, 149: 372-378.","journal-title":"Am J Epidemiol"},{"key":"2919_CR32","first-page":"757","volume":"10","author":"S Rinaldi","year":"2001","unstructured":"Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Secreto G, Ciampi A, Riboli E, Kaaks R: Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomark Prev. 2001, 10: 757-765.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2919_CR33","first-page":"1065","volume":"11","author":"S Rinaldi","year":"2002","unstructured":"Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R: Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1065-1071.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2307\/1403259","volume":"54","author":"A Donner","year":"1986","unstructured":"Donner A: A review of inference procedures for the intraclass correlation coefficient in the one-way random effects model. Int Stat Rev. 1986, 54: 67-82. 10.2307\/1403259.","journal-title":"Int Stat Rev"},{"key":"2919_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.steroids.2010.10.010","volume":"76","author":"M Rothman","year":"2011","unstructured":"Rothman M, Carlson N, Xu M, Wang C, Swerdloff R, Lee P, Goh VHH, Ridgway EC, Wierman M: Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011, 76: 177-182. 10.1016\/j.steroids.2010.10.010.","journal-title":"Steroids"},{"key":"2919_CR36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1055-9965.EPI-05-0848","volume":"15","author":"S Missmer","year":"2006","unstructured":"Missmer S, Spiegelman D, Bertone Johnson E, Barbieri R, Pollak M, Hankinson S: Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev. 2006, 15: 972-978. 10.1158\/1055-9965.EPI-05-0848.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR37","first-page":"2832","volume":"85","author":"HG Burger","year":"2000","unstructured":"Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL: A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000, 85: 2832-2838. 10.1210\/jc.85.8.2832.","journal-title":"J Clin Endocrinol Metab"},{"key":"2919_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1677\/ERC-06-0045","volume":"14","author":"RJ Santen","year":"2007","unstructured":"Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J, Breast Cancer Prevention Collaborative G: Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007, 14: 169-187. 10.1677\/ERC-06-0045.","journal-title":"Endocr Relat Cancer"},{"key":"2919_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001, 93: 358-366. 10.1093\/jnci\/93.5.358.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR40","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1186\/bcr2110","volume":"10","author":"B Rosner","year":"2008","unstructured":"Rosner B, Colditz GA, Iglehart JD, Hankinson SE: Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study. Breast Cancer Res. 2008, 10: R55-10.1186\/bcr2110.","journal-title":"Breast Cancer Res"},{"key":"2919_CR41","first-page":"79","volume":"18","author":"K Helzlsouer","year":"1994","unstructured":"Helzlsouer K, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994, 18: 79-85.","journal-title":"Cancer Detect Prev"},{"key":"2919_CR42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2005.03.7432","volume":"24","author":"AH Eliassen","year":"2006","unstructured":"Eliassen AH, Missmer S, Tworoger S, Hankinson S: Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?. J Clin Oncol. 2006, 24: 1823-1830. 10.1200\/JCO.2005.03.7432.","journal-title":"J Clin Oncol"},{"key":"2919_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3322\/caac.20063","volume":"60","author":"R Smith","year":"2010","unstructured":"Smith R, Cokkinides V, Brooks D, Saslow D, Brawley O: Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010, 60: 99-119. 10.3322\/caac.20063.","journal-title":"CA Cancer J Clin"},{"key":"2919_CR44","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999, 91: 1829-1846. 10.1093\/jnci\/91.21.1829.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1524-4741.2009.00857.x","volume":"16","author":"E Ozanne","year":"2010","unstructured":"Ozanne E, Wittenberg E, Garber J, Weeks J: Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J. 2010, 16: 38-47. 10.1111\/j.1524-4741.2009.00857.x.","journal-title":"Breast J"},{"key":"2919_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1055\/s-2006-939566","volume":"24","author":"F Stanczyk","year":"2006","unstructured":"Stanczyk F: Measurement of androgens in women. Semin Reprod Med. 2006, 24: 78-85. 10.1055\/s-2006-939566.","journal-title":"Semin Reprod Med"},{"key":"2919_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.steroids.2010.01.012","volume":"75","author":"I Blair","year":"2010","unstructured":"Blair I: Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids. 2010, 75: 297-306. 10.1016\/j.steroids.2010.01.012.","journal-title":"Steroids"},{"key":"2919_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1055-9965.EPI-08-0808","volume":"18","author":"S Sieri","year":"2009","unstructured":"Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P, Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P: Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2009, 18: 169-176. 10.1158\/1055-9965.EPI-08-0808.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2919_CR49","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnci\/djr031","volume":"103","author":"G Farhat","year":"2011","unstructured":"Farhat G, Cummings S, Chlebowski R, Parimi N, Cauley J, Rohan T, Huang A, Vitolins M, Hubbell FA, Manson J, Cochrane B, Lane D, Lee J: Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst. 2011, 103: 562-570. 10.1093\/jnci\/djr031.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR50","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.steroids.2011.02.029","volume":"76","author":"T Key","year":"2011","unstructured":"Key T: Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011, 76: 812-815. 10.1016\/j.steroids.2011.02.029.","journal-title":"Steroids"},{"key":"2919_CR51","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jnci\/djg022","volume":"95","author":"The Endogenous Hormones Breast Cancer Collaborative Group","year":"2003","unstructured":"The Endogenous Hormones Breast Cancer Collaborative Group: Body mass index, serum sex hormones, and breast cancer risk in postmonopausal women. J Natl Cancer Inst. 2003, 95: 1218-1226.","journal-title":"J Natl Cancer Inst"},{"key":"2919_CR52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/aje\/152.6.514","volume":"152","author":"PA van den Brandt","year":"2000","unstructured":"van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, Marshall JR, Miller AB, Rohan T, Smith-Warner SA, Speizer FE, Willett WC, Wolk A, Hunter DJ: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000, 152: 514-527. 10.1093\/aje\/152.6.514.","journal-title":"Am J Epidemiol"},{"key":"2919_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/sj.ijo.0803133","volume":"30","author":"B Tehard","year":"2006","unstructured":"Tehard B, Clavel Chapelon F: Several anthropometric measurements and breast cancer risk: results of the E3N cohort study. Int J Obes. 2006, 30: 156-163. 10.1038\/sj.ijo.0803133.","journal-title":"Int J Obes"},{"key":"2919_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1210\/er.2003-0016","volume":"25","author":"W Somboonporn","year":"2004","unstructured":"Somboonporn W, Davis S: Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 2004, 25: 374-388. 10.1210\/er.2003-0016.","journal-title":"Endocr Rev"},{"key":"2919_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0960-0760(01)00185-6","volume":"80","author":"D Liao","year":"2002","unstructured":"Liao D, Dickson R: Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002, 80: 175-189. 10.1016\/S0960-0760(01)00185-6.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2919_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000158055","volume":"3","author":"K Tiefenbacher","year":"2008","unstructured":"Tiefenbacher K, Daxenbichler G: The role of androgens in normal and malignant breast tissue. Breast Care. 2008, 3: 325-331.","journal-title":"Breast Care"},{"key":"2919_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.gme.0000232033.92411.51","volume":"14","author":"M Hofling","year":"2007","unstructured":"Hofling M, Hirschberg A, Skoog L, Tani E, Hagerstrom T, von Schoultz B: Testosterone inhibits estrogen\/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2007, 14: 183-190. 10.1097\/01.gme.0000232033.92411.51.","journal-title":"Menopause"},{"key":"2919_CR58","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0378-5122(01)00300-0","volume":"41","author":"C Campagnoli","year":"2002","unstructured":"Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra G, Genazzani A: Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas. 2002, 41: 299-311. 10.1016\/S0378-5122(01)00300-0.","journal-title":"Maturitas"},{"key":"2919_CR59","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7326\/0003-4819-148-8-200804150-00001","volume":"148","author":"S Davis","year":"2008","unstructured":"Davis S, Papalia M-A, Norman R, O'Neill S, Redelman M, Williamson M, Stuckey BGA, Wlodarczyk J, Gard'ner K, Humberstone A: Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Int Med. 2008, 148: 569-577.","journal-title":"Ann Int Med"},{"key":"2919_CR60","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1001\/archinte.166.14.1483","volume":"166","author":"R Tamimi","year":"2006","unstructured":"Tamimi R, Hankinson S, Chen W, Rosner B, Colditz G: Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Int Med. 2006, 166: 1483-1489. 10.1001\/archinte.166.14.1483.","journal-title":"Arch Int Med"},{"key":"2919_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archinternmed.2008.507","volume":"169","author":"R Ness","year":"2009","unstructured":"Ness R, Albano J, McTiernan A, Cauley J: Influence of estrogen plus testosterone supplementation on breast cancer. Arch Int Med. 2009, 169: 41-46. 10.1001\/archinternmed.2008.507.","journal-title":"Arch Int Med"},{"key":"2919_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1210\/jc.2006-1864","volume":"92","author":"W Rosner","year":"2007","unstructured":"Rosner W, Auchus R, Azziz R, Sluss P, Raff H: Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007, 92: 405-413.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr3117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr3117\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr3117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:51:34Z","timestamp":1728384694000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr3117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,2]]}},"alternative-id":["2919"],"URL":"https:\/\/doi.org\/10.1186\/bcr3117","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,16]]},"assertion":[{"value":"19 August 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R32"}}